Project Grant 2234041
Award Date
6/15/23
Completion Date
5/31/24
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
This Cooperative Agreement award of $1,250,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development and validation of a novel platform technology for the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf anti-cancer therapies. The project aims to accomplish two key objectives: 1) increase the efficacy of induced pluripotent stem cell (iPSC)-derived T cell therapy relative...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Cellecho, Inc., a minority-owned small business, to develop a microchip-based technology for advanced cell engineering. The project aims to create a platform that leverages acoustic-electric micro-vortices to precisely and efficiently deliver genetic materials like DNA, mRNA, and proteins to cells, enabling complex cell...
Progenitor Inc. received a $255,750 Small Business Innovation Research Phase I Project Grant from the National Science Foundation to develop off-the-shelf immuno-compatible cell therapies. The grant was awarded on February 1, 2021 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) and will fund the project through October 31, 2022 at Progenitor's facilities in Emigration Canyon, Utah. The NSF TIP program seeks to advance science and engineering research leading to...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $304,733 to Selight, LLC, a woman-owned small business located in Madison, WI, aims to develop a novel optical metabolic flow cytometer instrument to screen T cell fitness for chimeric antigen receptor (CAR) T-cell therapy. The project's broader impact is a rapid diagnostic method to identify patients who will benefit most from CAR T-cell therapy, which can fail in 15-69% of...
This $500,000 Project Grant from the National Science Foundation Division of Molecular and Cellular Biosciences, under the Biological Sciences federal grant program (CFDA 47.074), will support research to develop an end-to-end continuous manufacturing process for cell therapies using robotics and microfluidic technologies. The Georgia Tech Research Corporation will receive funding to create a more integrated workflow based on microfluidic device-enabled genetic engineering, cell expansion, and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $1,008,000 to Vcreate, Inc. aims to enable the discovery of T-cell receptor (TCR)-based immunotherapies for treating late-stage solid tumors. The project will apply a high-throughput screening platform developed in Phase I to identify clinically relevant TCRs by evaluating interactions with 62 cancer-related antigens. The most promising TCR candidates will then be...
This $250,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant supports the development of artificial substrates for growing human stem cells suitable for clinical applications at Oakland University from March 2023 to February 2025. The goal is to accelerate the potential benefits of using human pluripotent stem cells and their derivatives for treating and curing diseases by producing a synthetic substrate that supports growth of human pluripotent stem cells...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...